Immunicum AB - Product Pipeline Review - 2014

Published: Feb, 2014 | Pages: 21 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Immunicum AB - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Immunicum AB - Product Pipeline Review - 2014', provides an overview of the Immunicum AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Immunicum AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Immunicum AB including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Immunicum AB's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Immunicum AB's pipeline products

Reasons to buy

- Evaluate Immunicum AB's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Immunicum AB in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Immunicum AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Immunicum AB and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Immunicum AB
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Immunicum AB and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Immunicum AB Snapshot 4
Immunicum AB Overview 4
Key Information 4
Key Facts 4
Immunicum AB - Research and Development Overview 5
Key Therapeutic Areas 5
Immunicum AB - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Immunicum AB - Pipeline Products Glance 9
Immunicum AB - Clinical Stage Pipeline Products 9
Phase I Products/Combination Treatment Modalities 9
Immunicum AB - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Immunicum AB - Drug Profiles 11
Allogeneic Dendritic Cell Cancer Vaccine 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
CD70 Based Cancer Vaccine 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Tumor Antigen Pulsed Allogenic Dendritic Cell Vaccine 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Immunicum AB - Pipeline Analysis 15
Immunicum AB - Pipeline Products by Route of Administration 15
Immunicum AB - Pipeline Products by Molecule Type 16
Immunicum AB - Recent Pipeline Updates 17
Immunicum AB - Locations And Subsidiaries 19
Head Office 19
Appendix 20
Methodology 20
Coverage 20
Secondary Research 20
Primary Research 20
Expert Panel Validation 20
Contact Us 21
Disclaimer 21

List of Tables
Immunicum AB, Key Information 4
Immunicum AB, Key Facts 4
Immunicum AB - Pipeline by Indication, 2014 6
Immunicum AB - Pipeline by Stage of Development, 2014 7
Immunicum AB - Monotherapy Products in Pipeline, 2014 8
Immunicum AB - Phase I, 2014 9
Immunicum AB - Preclinical, 2014 10
Immunicum AB - Pipeline by Route of Administration, 2014 15
Immunicum AB - Pipeline by Molecule Type, 2014 16
Immunicum AB - Recent Pipeline Updates, 2014 17